Rene Russo - Jun 16, 2025 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role: PRESIDENT AND CEO, Director
Signature: /s/ Kevin Brennan, Attorney-in-Fact
Stock symbol: XLO
Transactions as of: Jun 16, 2025
Transactions value $: $24,680
Form type: 4
Date filed: 6/18/2025, 04:56 PM
Previous filing: Apr 16, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Russo Rene	PRESIDENT AND CEO, Director	828 WINTER STREET, SUITE 300, WALTHAM	/s/ Kevin Brennan, Attorney-in-Fact	2025-06-18	0001722066

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	XLO	Common Stock	Purchase	$24.7K	+36.3K	+14.82%	$0.68	281K	Jun 16, 2025	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6551 to $0.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6551 to $0.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.